IDO1 and cancer: However, setbacks in a recent clinical trial suggested an urgent need for more research to better understand what is the exact mechanism responsible for the immunosuppresion of IDO1 in cancer, how the TRP catabolism contributes to immune regulation mechanisms in the TME, what is the role of KYN and TRP in different cancer types, and to identify biomarkers to select patients that ultimately benefit from this treatment.